Company BioRestorative Therapies, Inc.

Stocks

BRTX

US0906557055

Biotechnology & Medical Research

Market Closed - Nasdaq 16:30:00 2026-10-30 EDT			5-day change	1st Jan Change
1.400 ^USD	-11.37%		-13.56%	-94.04%

10-09	BioRestorative Therapies, Inc. Announces Board and Committee Changes	CI
10-06	Maxim Downgrades BioRestorative Therapies to Hold From Buy	MT

Business description: BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.

Number of employees: 14

Sales by Activity: BioRestorative Therapies, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Biotechnology	46K	120K	146K	401K	360K

See all business segments

Geographical breakdown of sales: BioRestorative Therapies, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	46K	120K	146K	401K	360K

See all geographic segments

Executive Committee: BioRestorative Therapies, Inc.

Manager	Title	Age	Since
Mika Grasso CEO	Chief Executive Officer	28	2026-08-26
Anna Skowron DFI	Director of Finance/CFO	38	2026-08-26
Rory Rumore IRC	Investor Relations Contact	-	-
Crystal Romano PRN	Corporate Officer/Principal	-	2025-10-21

See BIORESTORATIVE THERAPIES, INC. governance

Composition of the Board of Directors: BioRestorative Therapies, Inc.

Director	Title	Age	Since
Mika Grasso BRD	Director/Board Member	28	2026-06-11
Jay Dhaliwal BRD	Director/Board Member	37	2026-06-11
Esha Randhawa BRD	Director/Board Member	-	2026-07-12
Steven Brown CHM	Chairman	32	2026-08-26
Don Currie BRD	Director/Board Member	65	2026-10-06

Composition of the Board of Directors

Shareholders: BioRestorative Therapies, Inc.

Name	Stocks	%	Valuation
Alta Partners LLC 4.844 %	66,907	4.844 %	155 893 $
Auctus Fund Management LLC 4.185 %	57,796	4.185 %	134 665 $
Jane Street Group LLC 2.909 %	40,176	2.909 %	93 610 $
HRT Financial LP 2.573 %	35,530	2.573 %	82 785 $
XTX Topco Ltd. 1.037 %	14,325	1.037 %	33 377 $

Name	Stocks	%	Valuation
Auctus Fund Management LLC 100 %	1,398,158	100 %	3 M $

List of BIORESTORATIVE THERAPIES, INC. shareholders

Company details: BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc.

40 Marcus Drive

11747, Melville

+631 760 8100

http://www.biorestorative.com

address BioRestorative Therapies, Inc.(BRTX)

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIORESTORATIVE THERAPIES, INC.	-11.37%	-13.56%	-95.45%	-96.46%	1.78M
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+42.87%	+64.15%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.40%	+81.76%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+16.24%	+103.35%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+47.83%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+19.28%	+98.80%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+225.14%	+866.21%	41B
GENMAB A/S	+3.27%	+47.96%	+112.84%	+96.58%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.57%	+46.95%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-40.62%	+349.24%	24.7B
Average	-0.83%	+5.43%	+33.28%	+165.84%	39.43B
Weighted average by Cap.	+0.18%	+5.44%	+47.99%	+176.67%